Purple Biotech Ltd.
Index- P/E- EPS (ttm)-0.77 Insider Own- Shs Outstand18.04M Perf Week-0.87%
Market Cap40.97M Forward P/E- EPS next Y- Insider Trans- Shs Float18.04M Perf Month-9.56%
Income- PEG- EPS next Q- Inst Own11.23% Short Float4.67% Perf Quarter-18.93%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio19.78 Perf Half Y-14.66%
Book/sh3.94 P/B0.58 EPS next Y- ROA- Target Price- Perf Year-53.58%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.10 - 5.18 Perf YTD-41.65%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.95% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low6.19% ATR0.13
Employees19 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)36.93 Volatility4.37% 5.11%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume338.01 Prev Close2.27
ShortableYes LT Debt/Eq- EarningsAug 04 BMO Payout- Avg Volume42.62K Price2.23
Recom- SMA20-10.03% SMA50-8.36% SMA200-27.70% Volume2,229,469 Change-1.76%
Aug-04-22 07:30AM  
Jul-14-22 07:30AM  
May-27-22 07:15AM  
May-18-22 08:18AM  
May-12-22 08:13AM  
Apr-11-22 07:37AM  
Feb-24-22 12:12AM  
Feb-09-22 07:00AM  
Feb-04-22 07:35AM  
Jan-06-22 07:30AM  
Dec-09-21 07:30AM  
Dec-06-21 07:30AM  
Nov-03-21 07:30AM  
Oct-26-21 08:27AM  
Oct-22-21 06:00AM  
Sep-24-21 07:38AM  
Sep-13-21 07:00AM  
Aug-05-21 08:30AM  
Jun-04-21 08:00AM  
May-26-21 07:38AM  
May-20-21 07:00AM  
May-19-21 07:00AM  
Apr-23-21 08:00AM  
Apr-13-21 08:17AM  
Mar-19-21 08:00AM  
Mar-11-21 08:02AM  
Mar-03-21 07:00AM  
Mar-02-21 07:00AM  
Jan-18-21 07:41AM  
Jan-04-21 09:40AM  
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.